RWJBarnabas Health, Rutgers open $225M cancer center

Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …

AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.


ASCO shockwave: Daraxonrasib survival curve draws standing ovation

7 wks / oncodaily

1 month / oncodaily

1 month / oncodaily


Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing

1 month / oncodaily

1 month / oncodaily

1 month / medicalxpress


Conference context: RAS momentum and expert reflections

1 month / oncodaily

1 month / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


Rapid off‑trial rollout and early patient access

7 wks / oncodaily

1 month / oncodaily

2 months / oncodaily

2 months / oncodaily


All Other Stories

7 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily

1 month / oncodaily

1 month / oncodaily

1 month / oncodaily

1 month / oncodaily

1 month / oncodaily

1 month / oncodaily

1 month / esmo

1 month / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


Back to Top / Sat, June 27, 2026, 3:21 pm / permalink 25982 / 32 stories in 2 months /




Related Stories


Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 2 months

FDA grants early access to experimental pancreatic cancer drug / 3 months

ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 8 days

Map of daraxonrasib resistance points to combo strategies in pancreatic cancer / 15 days

Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 1 month

Teclistamab shows survival benefit prompting earlier use discussions / 2 months

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Weight Loss, Diabetes, Government Policy, Health IT and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.